These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1203 related items for PubMed ID: 15752881

  • 1. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1019-34. PubMed ID: 15752881
    [Abstract] [Full Text] [Related]

  • 2. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
    Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC, Lebesque JV.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1142-52. PubMed ID: 15939547
    [Abstract] [Full Text] [Related]

  • 3. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD.
    Int J Radiat Oncol Biol Phys; 2005 Jul 01; 62(3):706-13. PubMed ID: 15936549
    [Abstract] [Full Text] [Related]

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 5. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):735-42. PubMed ID: 14967428
    [Abstract] [Full Text] [Related]

  • 6. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):39-45. PubMed ID: 18538488
    [Abstract] [Full Text] [Related]

  • 7. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
    Karlsdóttir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O.
    Radiother Oncol; 2004 Apr 01; 71(1):43-53. PubMed ID: 15066295
    [Abstract] [Full Text] [Related]

  • 8. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
    Karlsdóttir A, Muren LP, Wentzel-Larsen T, Dahl O.
    Int J Radiat Oncol Biol Phys; 2008 Apr 01; 70(5):1478-86. PubMed ID: 18060703
    [Abstract] [Full Text] [Related]

  • 9. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):400-8. PubMed ID: 15667959
    [Abstract] [Full Text] [Related]

  • 10. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.
    Int J Radiat Oncol Biol Phys; 2008 Mar 15; 70(4):1124-9. PubMed ID: 18313526
    [Abstract] [Full Text] [Related]

  • 11. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A.
    Radiother Oncol; 2005 Apr 15; 75(1):74-82. PubMed ID: 15878104
    [Abstract] [Full Text] [Related]

  • 12. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC, Schultheiss TE, Nguyen KH, Wong JY.
    Int J Radiat Oncol Biol Phys; 2008 Jun 01; 71(2):351-7. PubMed ID: 18164841
    [Abstract] [Full Text] [Related]

  • 13. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A, Tremblay C, Beaulieu L, Lachance B, Harel F, Lessard E, Pouliot J, Vigneault E.
    Radiother Oncol; 2005 Jun 01; 75(3):318-24. PubMed ID: 16086913
    [Abstract] [Full Text] [Related]

  • 14. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 15. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
    Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV.
    J Clin Oncol; 2006 May 01; 24(13):1990-6. PubMed ID: 16648499
    [Abstract] [Full Text] [Related]

  • 16. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):777-87. PubMed ID: 15465194
    [Abstract] [Full Text] [Related]

  • 17. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.
    Peeters ST, Lebesque JV, Heemsbergen WD, van Putten WL, Slot A, Dielwart MF, Koper PC.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1151-61. PubMed ID: 16414208
    [Abstract] [Full Text] [Related]

  • 18. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.
    Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2005 Jun 01; 62(2):392-6. PubMed ID: 15890580
    [Abstract] [Full Text] [Related]

  • 19. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):141-9. PubMed ID: 16111582
    [Abstract] [Full Text] [Related]

  • 20. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ, Weltman E, Hanriot RM, Luz FP, Cecílio PJ, da Cruz JC, Moreira FR, Santos AS, Martins LC, Nadalin W.
    Radiat Oncol; 2007 Jan 15; 2():6. PubMed ID: 17224072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.